Beena Goldenberg - OrganiGram Holdings CEO Director
| OGI Stock | USD 1.62 0.03 1.89% |
Insider
Beena Goldenberg is CEO Director of OrganiGram Holdings
| Age | 60 |
| Address | 145 King Street West, Toronto, ON, Canada, M5H 1J8 |
| Phone | 855-961-9420 |
| Web | https://www.organigram.ca |
OrganiGram Holdings Management Efficiency
The company has Return on Asset of (0.0556) % which means that on every $100 spent on assets, it lost $0.0556. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.5453) %, meaning that it generated no profit with money invested by stockholders. OrganiGram Holdings' management efficiency ratios could be used to measure how well OrganiGram Holdings manages its routine affairs as well as how well it operates its assets and liabilities. The OrganiGram Holdings' current Return On Tangible Assets is estimated to increase to -0.03. The OrganiGram Holdings' current Return On Capital Employed is estimated to increase to -0.07. As of now, OrganiGram Holdings' Other Current Assets are increasing as compared to previous years. The OrganiGram Holdings' current Intangibles To Total Assets is estimated to increase to 0.1, while Total Assets are projected to decrease to under 266.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Joseph Bayern | Curaleaf Holdings | 60 | |
| Lloyd Brathwaite | Tilray Inc | N/A | |
| Robbie Madan | SNDL Inc | 45 | |
| Joe Holland | Curaleaf Holdings | N/A | |
| Thomas Shipley | Canopy Growth Corp | 30 | |
| Rick Savone | Aurora Cannabis | N/A | |
| Ryan Hellard | SNDL Inc | 35 | |
| Edward Kremer | Curaleaf Holdings | 51 | |
| Kevin Gifford | Cronos Group | N/A | |
| Denise Faltischek | Tilray Inc | 51 | |
| William Newlands | Canopy Growth Corp | 62 | |
| Thomas Stewart | Canopy Growth Corp | 42 | |
| Jimes Sabia | Canopy Growth Corp | 58 | |
| Robert Hanson | Canopy Growth Corp | 57 | |
| Andrew Stordeur | SNDL Inc | 44 | |
| Julious Grant | Canopy Growth Corp | 56 | |
| Bernard Yeung | Tilray Inc | N/A | |
| FCPA FCA | Canopy Growth Corp | 63 | |
| Theresa Yanofsky | Canopy Growth Corp | 63 | |
| Tara Rozalowsky | Canopy Growth Corp | N/A | |
| Shayne Laidlaw | Cronos Group | N/A | |
Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.0556 |
OrganiGram Holdings Leadership Team
Elected by the shareholders, the OrganiGram Holdings' board of directors comprises two types of representatives: OrganiGram Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OrganiGram. The board's role is to monitor OrganiGram Holdings' management team and ensure that shareholders' interests are well served. OrganiGram Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OrganiGram Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Beena Goldenberg, CEO Director | ||
| Helen Martin, Chief Secretary | ||
| Katrina McFadden, Chief Officer | ||
| Megan McCrae, Senior Communications | ||
| Amy Schwalm, VP Relations | ||
| CFA CA, Chief Officer | ||
| Tina Shannon, VP HR | ||
| Nathalie Batten, Senior Operations | ||
| Timothy Emberg, Chief Officer | ||
| Gregory Engel, Special Advisor | ||
| Nathalie Kubrick, Senior Operations | ||
| Geoff Riggs, Chief Officer | ||
| Max Schwartz, Director Relations |
OrganiGram Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OrganiGram Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.0556 | ||||
| Profit Margin | (1.54) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 132.57 M | ||||
| Shares Outstanding | 126.16 M | ||||
| Shares Owned By Insiders | 34.20 % | ||||
| Shares Owned By Institutions | 9.70 % | ||||
| Number Of Shares Shorted | 2.69 M | ||||
| Price To Earning | (79.96) X |
Currently Active Assets on Macroaxis
When determining whether OrganiGram Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OrganiGram Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organigram Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organigram Holdings Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OrganiGram Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OrganiGram Holdings. If investors know OrganiGram will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OrganiGram Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Revenue Per Share 1.835 | Quarterly Revenue Growth (0.14) | Return On Assets (0.06) | Return On Equity (0.55) |
The market value of OrganiGram Holdings is measured differently than its book value, which is the value of OrganiGram that is recorded on the company's balance sheet. Investors also form their own opinion of OrganiGram Holdings' value that differs from its market value or its book value, called intrinsic value, which is OrganiGram Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OrganiGram Holdings' market value can be influenced by many factors that don't directly affect OrganiGram Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OrganiGram Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if OrganiGram Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OrganiGram Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.